In 1989, Professor Gosling co-founded the anticancer drug discovery group at Newcastle that has become internationally recognised by virtue of its discoveries of inhibitors of numerous cancer-related targets, notably poly(ADP-ribose) polymerase (PARP-1). The PARP research led, in collaboration with Agouron Pharmaceuticals, to rucaparib (Rubraca), which recently acquired FDA and EMA approval for the treatment of BRCA-mutant ovarian cancer.
If you would like meet Professor Gosling please contact the seminar organiser.
If you would like meet Professor Gosling please contact the seminar organiser.
